Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE: ABBV) received a positive opinion from the EMA's CHMP for risankizumab (SKYRIZI®) to treat adults with moderately to severely active Crohn's disease. The recommendation stems from three Phase 3 studies showing significant improvements in clinical remission and endoscopic response at 12 weeks post-treatment. If approved, this would be the first specific IL-23 inhibitor available for Crohn's disease in the EU. A final European Commission decision is expected in Q4 2022, marking the third indication for risankizumab in the region.
AbbVie announced it will present findings from the Phase 3 M15-736 trial and data on BOTOX at the 2022 MDS International Congress in Madrid from September 15-18. Key presentations include results on the continuous infusion of ABBV-951 for advanced Parkinson's disease and real-world efficacy of BOTOX for spasticity and cervical dystonia. AbbVie emphasizes its commitment to addressing the needs of patients with movement disorders, reinforcing its leadership in neuroscience.
AbbVie has opened public voting for its 30th annual Cystic Fibrosis (CF) Scholarship program, running until September 28. This year, 40 students living with CF are competing for two $25,000 scholarships based on academic excellence and community involvement. Earlier in 2022, AbbVie awarded $3,000 to 40 CF students, totaling over $3.7 million in scholarships since the program's inception. The winners will be announced in early November, highlighting AbbVie's commitment to supporting the CF community.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), announced the selection of 25 real patients for its new BOTOX® Cosmetic 'See Yourself' campaign after receiving nearly 20,000 submissions. The campaign aims to showcase authentic testimonials and experiences, reflecting the emotional and physical impact of BOTOX® treatments. The latest content includes interviews, treatment diaries, and informative sessions addressing common patient inquiries. BOTOX® Cosmetic remains the leading product in its category, approved by the FDA for treating facial lines.
AbbVie announced 100-week results from KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI (risankizumab) in adults with active psoriatic arthritis. Over 50% of patients achieved a 90% reduction in psoriasis severity (PASI 90), with similar joint symptom improvement (ACR20) as at week 52. The treatment maintained long-term efficacy, with no new safety signals observed. Serious treatment-emergent adverse events were low, with a rate of 7.6 E/100PY in KEEPsAKE 1. These findings were presented at the 31st EADV Congress, highlighting SKYRIZI's potential as a long-term treatment option.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.41 per share, payable on November 15, 2022, to shareholders of record by October 14, 2022. Since its inception in 2013, AbbVie has increased its dividend by over 250%. The company is a member of the S&P Dividend Aristocrats Index, which includes firms that have consistently raised dividends for at least 25 consecutive years.
AbbVie's MEASURE-AD study, spanning three years and 28 countries, highlights the significant clinical, psychosocial, and economic burdens faced by patients with moderate to severe atopic dermatitis, particularly those not on systemic therapy. Results presented at the EADV Congress indicate that these patients experience higher disease severity scores and lower quality of life, emphasizing the need for improved treatment options. The analysis shows that only half of eligible patients receive systemic therapy, revealing potential undertreatment in this population.
AbbVie announced new data from its migraine portfolio at the Migraine Trust International Symposium 2022 in London, from September 8-11. The presentation will include results from the Phase 3 PROGRESS trial for atogepant, aimed at preventing chronic migraine, alongside additional studies on onabotulinumtoxinA and ubrogepant. The company will highlight its commitment to addressing the unmet needs of migraine patients. A medical symposium titled "Evolving Faces of Migraine" will also take place during the event.
Summary not available.
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 9:35 a.m. Central time. Key speakers include Rob Michael, Jeff Stewart, and Neil Gallagher. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later in the day.
AbbVie aims to deliver innovative medicines across various fields like immunology, oncology, and neuroscience, enhancing patient care and addressing health challenges.